As the diagnostic testing paradigm for chromosomal translocations and other complex structural variants continues to shift from single-site Fluorescent In Situ Hybridization (FISH) and targeted RT-PCR to highly multiplexed next-generation sequencing (NGS) assays, there is increasing need for highly multiplexed reference materials for these difficult mutations.
The Seraseq FFPE Tumor Fusion RNA Reference Material v4 contains 18 clinically significant RNA fusions which are prevalent across different types of solid tumors, in an efficient single-sample format. RNA transcripts carrying structural variants are engineered into well-characterized wild-type cells. Cells are formalin-fixed and embedded in paraffin, and the FFPE block is cut into 10-micron sections, each of which typically yields >400 ng of purified total RNA. The transcript level for each fusion is quantified using highly sensitive digital PCR to establish ground-truth (and orthogonally validated with NGS), which helps ensure the material remains constant over time.
18 clinically relevant fusions evaluate assay sensitivity and specificity for important diagnostic, prognostic, and therapeutic targets
Full-process FFPE format may be treated like a clinical specimen, which can reveal pre-analytic variability
Quantification of transcript levels by dPCR establishes ground-truth and simplifies dilutions for Limit of Detection (LoD) experiments
Well-characterized GM24385 human genomic DNA as background wild-type material
Manufactured in GMP-compliant and ISO 13485-certified facilities
For research use only. Not for use in diagnostic procedures.
Seraseq FFPE OSHA HazCom Standard 29 CFR 1910.1200 and GHS Rev 3